ETF Analysis: The Schwab US Large-Cap ETF (SCHX) has an implied analyst target price of $28.23 per unit, indicating a potential upside of 10.46% from its current trading price of $25.56.
Notable Holdings: Key underlying holdings with significant upside include Atlassian Corp (TEAM), Repligen Corp (RGEN), and Roivant Sciences Ltd (ROIV), with expected increases of 44.73%, 44.01%, and 43.55% respectively.
Market Sentiment: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information or fail to account for recent developments.
Investor Consideration: Investors are encouraged to conduct further research to determine the validity of analysts' targets and whether they align with current market conditions.
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ROIV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ROIV is 27.63 USD with a low forecast of 22.00 USD and a high forecast of 33.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 22.970
Low
22.00
Averages
27.63
High
33.00
Current: 22.970
Low
22.00
Averages
27.63
High
33.00
Guggenheim
Buy
maintain
$25 -> $28
2025-12-18
Reason
Guggenheim
Price Target
$25 -> $28
AI Analysis
2025-12-18
maintain
Buy
Reason
Guggenheim raised the firm's price target on Roivant Sciences to $28 from $25 and keeps a Buy rating on the shares. The firm has increased its valuation for brepocitinib in dermatomyositis to $9 from $6 per share to reflect its rare disease-pricing and also made a slight adjustment of IMVT-1402 valuation across multiple indications, the analyst tells investors.
Leerink
David Risinger
maintain
$29 -> $32
2025-12-15
Reason
Leerink
David Risinger
Price Target
$29 -> $32
2025-12-15
maintain
Reason
Leerink analyst David Risinger raised the firm's price target on Roivant Sciences to $32 from $29 and keeps an Outperform rating on the shares. The firm cites higher long-term profitability following Roivant Sciences' encouraging analyst meeting on December 11.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ROIV
Unlock Now
JPMorgan
Overweight
maintain
$26
2025-12-12
Reason
JPMorgan
Price Target
$26
2025-12-12
maintain
Overweight
Reason
JPMorgan extended Roivant Sciences as a top pick from 2025 to 2026 following the company's investor day. The firm also added Roivant to its Analyst Focus List as a growth idea. JPMorgan has an Overweight rating on the shares with a $26 price target. Roivant's business structure "should stand out on its own." the analyst tells investors in a research note. The firm says multiple catalysts" were pulled forward to 2026 across the company's core Vants.
H.C. Wainwright
Buy
maintain
$23 -> $26
2025-12-12
Reason
H.C. Wainwright
Price Target
$23 -> $26
2025-12-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Roivant Sciences to $26 from $23 and keeps a Buy rating on the shares. The firm increased revenue estimates for IMVT-1402 in Graves' disease. Brepocitinib's Phase 3 win in dermatomyositis is a "game-changer" for Roivant, and the analyst meeting underscored management's plan to replicate that success, the analyst tells investors in a research note.
About ROIV
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
